A Phase I Study of LY3405105 in Patients with Advanced Cancer

Full Title

A Phase 1a/1b Study of LY3405105 Administered to Patients with Advanced Solid Tumors

Purpose

The purpose of this study is to find the highest dose of the investigational drug LY3405105 besylate and the best dosing schedule that can be used in patients with advanced solid tumors that have continued to grow despite prior treatment. LY3405105 is called a CDK7 inhibitor. CDK7 is a protein found in cells that researchers believe helps cancer to grow. Blocking CDK7 may stop or slow the growth of a tumor.

LY3405105 is taken orally (by mouth). Patients in this study will take it either once a day or three times a week.

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have an advanced solid tumor that cannot be cured using standard therapies. The study group will include patients with triple-negative breast cancer and high-grade ovarian cancer.
  • At least 3 weeks must pass between the completion of previous treatment and receipt of the study drug.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Alison Schram at 646-888-5388.

Protocol

19-099

Phase

I

Disease Status

Relapsed or Refractory

Investigator

Co-Investigators